129299-06-5 Usage
General Description
The chemical (3R,4S,5S,6R)-5-methoxy-4-[(2R,3R)-2-methyl-3-(3-methylbut-2-en-1-yl)oxiran-2-yl]-1-oxaspiro[2.5]oct-6-yl carbamate is a complex organic compound with a unique molecular structure. It contains a carbamate functional group and a spiro ring system, which gives it distinct chemical properties. The presence of methoxy and oxiran groups suggests potential for biological activity and reactivity. (3R,4S,5S,6R)-5-methoxy-4-[(2R,3R)-2-methyl-3-(3-methylbut-2-en-1-yl)oxiran-2-yl]-1-oxaspiro[2.5]oct-6-yl carbamate may have applications in drug development, organic synthesis, and medicinal chemistry due to its intricate structure and potential pharmacological properties. Its synthesis and chemical properties make it a valuable target for further research and potential applications in various scientific and industrial fields.
Check Digit Verification of cas no
The CAS Registry Mumber 129299-06-5 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,2,9,2,9 and 9 respectively; the second part has 2 digits, 0 and 6 respectively.
Calculate Digit Verification of CAS Registry Number 129299-06:
(8*1)+(7*2)+(6*9)+(5*2)+(4*9)+(3*9)+(2*0)+(1*6)=155
155 % 10 = 5
So 129299-06-5 is a valid CAS Registry Number.
129299-06-5Relevant articles and documents
POLYMER-CONJUGATED METAP2 INHIBITORS, AND THERAPEUTIC METHODS OF USE THEREOF
-
Paragraph 0228; 0229, (2017/09/25)
One aspect of the invention provides polymer conjugated MetAP2 inhibitors. While not being bound by any particular theory, it is believed that coupling the MetAP2 inhibitory core via the linkers described herein provides compounds with superior efficacy to the parent small molecules and superior pharmacokinetic profiles. In one aspect of the invention, the polymer conjugated MetAP2 inhibitors are useful in methods of treating disease, comprising administering to a subject in need thereof a therapeutically effective amount of a polymer conjugated MetAP2 inhibitor.